GlassScriptPhysician profile
Thomas Montgomery Crowley
NPI 1558148593
$1,529.19
in general payments reported to CMS, 2019-2025
33 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $366 · 2024: $867 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228 · Education: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.71 |
| Education | $301.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $203.91 | 2023-2024 | Jaypirca, Retevmo, Verzenio |
| Janssen Biotech, INC. | $166.52 | 2023-2024 | Darzalex, Erleada, Tecvayli |
| Abbvie INC. | $163.94 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $105.38 | 2023-2024 | |
| Glaxosmithkline, LLC. | $72.16 | 2024-2025 | Jemperli, Zejula, Blenrep |
| Pfizer INC. | $51.86 | 2023-2025 | |
| Axsome Therapeutics, INC. | $51.10 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $47.33 | 2023-2024 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $46.16 | 2023 | Injectafer, Enhertu |
| Teva Pharmaceuticals USA, INC. | $45.61 | 2025 | Uzedy, Austedo Xr |
| Incyte Corporation | $43.43 | 2023-2024 | Jakafi |
| Gilead Sciences, INC. | $42.93 | 2024 | |
| Coherus Oncology, INC. | $42.72 | 2023 | |
| Janssen Pharmaceuticals, INC | $37.59 | 2024-2025 | Xarelto, Invega Sustenna |
| Janssen Scientific Affairs, LLC | $36.00 | 2024 | Darzalex, Balversa, Talvey |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $27.62 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $27.61 | 2023 | Tazverik |
| Neuronetics, INC. | $25.04 | 2025 | Neurostar Tms Therapy System |
| Noven Therapeutics, LLC | $23.78 | 2025 | Xelstrym, Secuado |
| Seagen INC. | $22.35 | 2023 | Tukysa |
| Otsuka America Pharmaceutical, INC. | $21.11 | 2025 | Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.03 | 2025 | Caplyta |
| Pharmaessentia USA Corporation | $21.01 | 2024 | Besremi |
| Genzyme Corporation | $20.18 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $20.13 | 2024 | |
| Vanda Pharmaceuticals INC. | $19.99 | 2025 | Fanapt |
| Rigel Pharmaceuticals, INC. | $19.47 | 2024 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $18.89 | 2023 | Fruzaqla |
| Pharmacosmos Therapeutics INC. | $18.86 | 2023 | Monoferric |
| Astellas Pharma US INC | $17.57 | 2024 | Xtandi |
| Servier Pharmaceuticals LLC | $16.85 | 2024 | |
| Genmab U.S., INC. | $16.42 | 2024 | Epkinly |
| Kyowa Kirin, INC. | $14.64 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Crowley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.